1 min read
Add as a preferred source on Google

FDA Grants Accelerated Approval to GSK’s Neladalkib for Lung Cancer

GSK completed its $10.6 billion acquisition of Nuvalent in July, adding three lung cancer assets to its portfolio.

A lung scan sits behind an unmarked glass medicine vial / TokenPost.ai (mono)
A lung scan sits behind an unmarked glass medicine vial / TokenPost.ai (mono)

The U.S. Food and Drug Administration granted accelerated approval Tuesday to neladalkib, a lung cancer therapy owned by GSK after its acquisition of Nuvalent.

GSK completed the purchase July 15, at an equity value of about $10.6 billion. The acquisition added three lung cancer assets to GSK’s portfolio. At closing, two were under FDA review and one was in Phase 1.

The approval follows the acquisition, which expanded GSK’s oncology pipeline with Nuvalent’s lung cancer portfolio. More details about the transaction are in TokenPost’s earlier coverage of the deal.

Riza Dagoc

Riza Dagoc reports on regulation, investing and the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

Loading…